2022
Maternal Diabetes in Youth-Onset Type 2 Diabetes Is Associated With Progressive Dysglycemia and Risk of Complications
Shah R, Chernausek S, ghormli L, Geffner M, Keady J, Kelsey M, Farrell R, Tesfaldet B, Tryggestad J, Van Name M, Isganaitis E. Maternal Diabetes in Youth-Onset Type 2 Diabetes Is Associated With Progressive Dysglycemia and Risk of Complications. The Journal Of Clinical Endocrinology & Metabolism 2022, 108: 1120-1131. PMID: 36446741, PMCID: PMC10306086, DOI: 10.1210/clinem/dgac663.Peer-Reviewed Original ResearchConceptsYouth-onset type 2 diabetesType 2 diabetesMaternal diabetesHeart rate variabilityGlomerular hyperfiltrationParental diabetesGlycemic controlRate variabilityFuture cardiometabolic diseaseParental diabetes historyYouth-onset T2D.Lower heart rate variabilityRisk of complicationsWorse glycemic controlΒ-cell functionRace/ethnicityDiabetes historyCardiometabolic diseasesDiabetes outcomesPrenatal exposureUS cohortGlycemic outcomesRisk factorsDisease progressionUS CentersYouth with type 2 diabetes have a high rate of treatment failure after discontinuation of insulin: A Pediatric Diabetes Consortium study
Wolf RM, Cheng P, Gal RL, Beaulieu LC, Kollman C, Isganaitis E, Magge S, Mastrandrea LD, Klingensmith GJ, Tamborlane W, Van Name M, Consortium P. Youth with type 2 diabetes have a high rate of treatment failure after discontinuation of insulin: A Pediatric Diabetes Consortium study. Pediatric Diabetes 2022, 23: 439-446. PMID: 35138021, DOI: 10.1111/pedi.13325.Peer-Reviewed Original ResearchConceptsIntensive lifestyle interventionTreatment failureType 2 diabetesDiabetes medicationsLifestyle interventionGlycemic controlDiscontinuation of insulinExperienced treatment failureInitial insulin treatmentYouth-onset T2DHigh rateMetformin monotherapyPrimary outcomeMedian timeRisk factorsInsulin treatmentMetforminProgressive natureConsortium studyLogistic regressionInsulinT2DIntensive lifestyleMedicationsDiabetes
2021
Long-Term Complications in Youth-Onset Type 2 Diabetes
Bjornstad P, Drews K, Caprio S, Gubitosi-Klug R, Nathan D, Tesfaldet B, Tryggestad J, White N, Zeitler P. Long-Term Complications in Youth-Onset Type 2 Diabetes. New England Journal Of Medicine 2021, 385: 416-426. PMID: 34320286, PMCID: PMC8697255, DOI: 10.1056/nejmoa2100165.Peer-Reviewed Original ResearchConceptsType 2 diabetesDiabetic kidney diseaseNerve diseaseKidney diseaseRetinal diseasesYouth-Onset Type 2Minority raceDevelopment of complicationsIncidence of dyslipidemiaRisk of complicationsMulticenter clinical trialDiagnosis of diabetesMicrovascular complicationsAdverse eventsCumulative incidenceTerm complicationsGlycemic controlRelated complicationsObservational followMean ageRisk factorsClinical trialsComplicationsDyslipidemiaHypertension
2020
Children and adolescents with type 1 and type 2 diabetes mellitus in the Pediatric Diabetes Consortium Registries: comparing clinical characteristics and glycaemic control
Van Name MA, Cheng P, Gal RL, Kollman C, Lynch J, Nelson B, Tamborlane WV, Consortium F. Children and adolescents with type 1 and type 2 diabetes mellitus in the Pediatric Diabetes Consortium Registries: comparing clinical characteristics and glycaemic control. Diabetic Medicine 2020, 37: 863-867. PMID: 31943374, DOI: 10.1111/dme.14233.Peer-Reviewed Original ResearchConceptsType 2 diabetesType 1 diabetesPediatric Diabetes ConsortiumTarget HbAType 1Median C-peptide levelsResidual endogenous insulin secretionType 2 diabetes mellitusC-peptide levelsEndogenous insulin secretionOverweight/obeseYears of agePoor diabetes outcomesSubset of participantsCharacteristics of childrenDiabetic ketoacidosisGlycaemic controlClinical characteristicsDiabetes mellitusDiabetes outcomesRisk factorsFamilies of childrenInsulin secretionInsulin treatmentDiabetes diagnosis
2018
T1D and T2D Youth in the Pediatric Diabetes Consortium (PDC) Registries—Comparing Clinical Characteristics and Glycemic Control
TAMBORLANE W, CHENG P, GAL R, KOLLMAN C, VAN NAME M, LYNCH J, NELSON B. T1D and T2D Youth in the Pediatric Diabetes Consortium (PDC) Registries—Comparing Clinical Characteristics and Glycemic Control. Diabetes 2018, 67 DOI: 10.2337/db18-1340-p.Peer-Reviewed Original ResearchTarget HbA1c levelT2D youthHbA1c levelsMedtronic MiniMedResidual endogenous insulin secretionHigher mean HbA1c levelsBoehringer Ingelheim GmbHMean HbA1c levelEndogenous insulin secretionOverweight/obesePoor diabetes outcomesChi-square testMann-Whitney UBoehringer Ingelheim PharmaceuticalsT2D durationClinical characteristicsInsulin therapyGlycemic controlT1D patientsDiabetes careDiabetes outcomesRisk factorsC-peptideInsulin secretionLogistic regression